MP16-17 PHASE I STUDY OF INTRAVESICAL FC-OPTIMIZED ANTI-CD40 AGONIST ANTIBODY 2141-V11 FOR NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG).

Authors :: Bochner, Bernard H.
Alam, Muneeb
Osorio, Juan C.
Wong, Jeffrey L.
Knorr, David
Blanchard, Lucas
Angulo-Lozano, Juan
Whiting, Karissa
Seshan, Venkatraman E.
Donahue, Timothy
Cha, Eugene
Goh, Alvin
Smith, Robert
Dalbagni, Guido
Hernandez, Christian
McCarter, Melissa
Pietzak, Eugene J.
Rosenberg, Jonathan E.
Ravetch, Jeffrey V.
Source :: Journal of Urology; 2024 Supplement 5, Vol. 211, pe247-e247, 1p
Publication Year :: 2024

Subjects :: NON-muscle invasive bladder cancer
BLADDER cancer
BCG immunotherapy

Full Text Access

Tools